Pharmaceutical News

RSS

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Edison Pharmaceuticals has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).

20 May 2014

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Cardiome Pharma Corp. today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets.

20 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Novel drug for patients with inoperable CTEPH shows improvement in international trial

After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US.

20 May 2014

New technique can predict which stroke victims will benefit from clot-busting drugs

Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.

20 May 2014

TSRI chemists develop correct structure of highly promising anticancer compound

Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.

20 May 2014

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

20 May 2014

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Taking olive oil supplements may counteract some of the adverse cardiovascular effects of exposure to air pollution, according to a new study presented at the 2014 American Thoracic Society International Conference.

19 May 2014

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones.

19 May 2014

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.

19 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

TOLMAR Pharmaceuticals holds exclusive distribution rights to ELIGARD in the U.S. and Puerto Rico

TOLMAR Pharmaceuticals, Inc., focused on specialty pharmaceutical products, today announced that, effective May 8, 2014, the company holds exclusive distribution rights to ELIGARD® (leuprolide acetate for injectable suspension) in the U.S. and Puerto Rico.

16 May 2014

Pharmaceutical News

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Existing pharmaceutical drugs may offer effective therapies against MERS

Novel drug for patients with inoperable CTEPH shows improvement in international trial

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

New technique can predict which stroke victims will benefit from clot-busting drugs

TSRI chemists develop correct structure of highly promising anticancer compound

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Study shows commonly used statin drug does not reduce acute COPD exacerbations

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

TOLMAR Pharmaceuticals holds exclusive distribution rights to ELIGARD in the U.S. and Puerto Rico

New collaboration between Australian and European scientists to boost therapeutic drug research

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

Anticoagulation therapy with low-dose aspirin can be used with new generation mechanical heart valve

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News